The Philippine government’s procurement of over P3 billion in vials for a mass immunization program is the subject of probe by both chambers of Congress. The program, controversial since its inception over concerns by experts regarding the lack of long-term studies on the vaccine, was stopped after Sanofi itself revealed in December 2017 that the vaccine was not safe for those who had yet to be infected with the dengue virus.